Press Releases | PTC Therapeutics, Inc.

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date	Title and Summary	View
Feb 22, 2022	PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results - $539 million 2021 total revenue representing impressive 41% year-over-year growth - - Continued pipeline progress with five registration-directed clinical trials ongoing - - $700-750 million 2022 total revenue guidance reaffirmed - SOUTH PLAINFIELD, N.J. , Feb.
Feb 08, 2022	PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2021 Financial Results SOUTH PLAINFIELD, N.J. , Feb. 8, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and year-end 2021 financial results and provide an update on the company's business and outlook on Tuesday,
Jan 25, 2022	FDA Grants Evrysdi® Priority Review Based on Results From Treating Pre-Symptomatic Infants with Spinal Muscular Atrophy - RAINBOWFISH study interim results showed that after treatment with Evrysdi pre-symptomatic infants with spinal muscular atrophy achieved same motor milestones as healthy infants - SOUTH PLAINFIELD, N.J. , Jan. 25, 2022 /PRNewswire/ -- PTC Therapeutics, Inc.
Jan 18, 2022	PTC Therapeutics Announces Launch of 8th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community - 2022 grant program will focus on Innovation and Transition to Adulthood initiatives - - Submissions due on March 18, 2022 - SOUTH PLAINFIELD, N.J. , Jan. 18, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the eighth annual STRIVE ™ awards program for
Jan 13, 2022	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH PLAINFIELD, N.J. , Jan. 13, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 7, 2022 , the company approved non-statutory stock options to purchase an aggregate of 18,255 shares of its common stock and 10,675 restricted stock units ("RSUs"), each
Jan 13, 2022	PTC Therapeutics Announces Launch of 2022 Global Talent Pipeline Program - One-year fellowship provides diverse work experiences across PTC's business areas - SOUTH PLAINFIELD, N.J. , Jan. 13, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the company's 2022 Talent Pipeline Program, a one-year, global initiative designed to
Jan 10, 2022	PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 40th Annual J.P. Morgan Healthcare Conference - $536 million unaudited 2021 total revenue representing impressive 41% year-over-year growth - - $700 - 750 million 2022 total revenue guidance - - Results are expected in four registration-directed trials this year - - Three additional registration-directed clinical trials expected to initiate in
Jan 04, 2022	Waylivra™ Receives Innovative Drug Category Pricing to Treat Familial Chylomicronemia Syndrome in Brazil - Additional application submitted to ANVISA for a new indication to treat familial partial lipodystrophy - SOUTH PLAINFIELD, N.J. , Jan. 4, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Waylivra™ (volanesorsen) has successfully received Category 1 classification
Jan 03, 2022	PTC Therapeutics to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference SOUTH PLAINFIELD, N.J. , Jan. 3, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the 40 th Annual J.P. Morgan Virtual Healthcare Conference on Monday, Jan. 10 , at 7:30 a.m. EST .
Dec 20, 2021	Oral Splicing Modifiers that Systemically Lower Huntington Disease Protein Discovered Through PTC Therapeutics' Innovative Splicing Platform -- Results published in Nature Communications -- -- Description of novel splicing mechanism causing inhibition of HTT gene expression -- SOUTH PLAINFIELD, N.J. , Dec. 20, 2021 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced the Nature Communications publication characterizing